{{Rsnum
|rsid=1649942
|Gene=NRG3
|Chromosome=10
|position=83951691
|Orientation=minus
|GMAF=0.2553
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 8.0 | 38.9 | 53.1
| HCB | 8.8 | 26.5 | 64.7
| JPT | 7.2 | 20.7 | 72.1
| YRI | 12.2 | 40.8 | 46.9
| ASW | 10.5 | 38.6 | 50.9
| CHB | 8.8 | 26.5 | 64.7
| CHD | 10.1 | 17.4 | 72.5
| GIH | 2.0 | 29.7 | 68.3
| LWK | 24.5 | 39.1 | 36.4
| MEX | 3.4 | 29.3 | 67.2
| MKK | 14.8 | 51.0 | 34.2
| TSI | 7.8 | 38.2 | 53.9
| HapMapRevision=28
}} 
Gamazon ER et al., Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. ''Proceedings of the National Academy of Sciences'' [http://www.pnas.org/content/early/2010/05/03/1001827107.abstract]
associated with carboplatin sensitivity. M. Eileen Dolan proceedings of [http://askja.gene.le.ac.uk/hgv2009/ hgv2009]  

{{PMID Auto
|PMID=21705454
|Title=Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients
|OA=1
}}

{{PMID|17701890|OA=1
}} Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach.

{{PMID Auto
|PMID=22752226
|Title=Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}